Albireo to Report Q4 and Year-End 2021 Financial Results on March 1
22 Februar 2022 - 2:30PM
Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company
developing novel bile acid modulators, today announced that
management will host a conference call and live audio webcast
at 10:00 a.m. ET on March 1, 2022, to provide a business
update and review the company’s financial results for the fourth
quarter and year ended December 31, 2021.
To access the live conference call by phone, dial
877-407-0792 (domestic) or 201-689-8263 (international), and
provide the access code 13727211. A live audio webcast will be
accessible from the Media & Investors page of Albireo’s
website ir.albireopharma.com/. To ensure a timely connection
to the webcast, it is recommended that participants register at
least 15 minutes prior to the scheduled start time. An archived
version of the webcast will be available for replay on the Events
& Presentations section of the Media & Investors page of
Albireo’s website for 3 months following the event.
About Albireo Albireo Pharma is a rare disease
company focused on the development of novel bile acid modulators to
treat rare pediatric and adult liver diseases. Albireo’s lead
product, Bylvay, was approved by the U.S. FDA as the first drug for
the treatment of pruritus in all types of progressive familial
intrahepatic cholestasis (PFIC), and it is also being developed to
treat other rare pediatric cholestatic liver diseases with Phase 3
trials in Alagille syndrome and biliary atresia, as well as an
Open-label Extension (OLE) study for PFIC. In Europe, Bylvay has
been approved for the treatment of PFIC with pricing listing in
Germany and guidance from the National Institute for Health and
Care Excellence (NICE) recommending Bylvay for use in the National
Health Service in the England, Wales and Northern Ireland UK. The
Company has also completed a Phase 1 clinical trial for A3907 to
advance development in adult cholestatic liver disease, with
IND-enabling studies progressing with A2342 for viral and
cholestatic liver disease. Albireo was spun out from AstraZeneca in
2008 and is headquartered in Boston, Massachusetts, with its key
operating subsidiary in Gothenburg, Sweden. The Boston Business
Journal named Albireo one of the 2019 and 2020 Best Places to Work
in Massachusetts. For more information on Albireo, please visit
www.albireopharma.com.
Media Contact:Colleen Alabiso,
857-356-3905, colleen.alabiso@albireopharma.com Lance
Buckley, 917-439-2241,
lbuckley@lippetaylor.com Investor
Contact:Hans Vitzthum, LifeSci Advisors, LLC.,
617-430-7578
Albireo Pharma (NASDAQ:ALBO)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Albireo Pharma (NASDAQ:ALBO)
Historical Stock Chart
Von Apr 2023 bis Apr 2024